Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.

Featured Documents

There are currently no items available.

Share Price

Stock chart for: LJPC.OQ.  Currently trading at $37.21 with a 52 week high of $39.26 and a 52 week low of $14.65.
Price$37.21
Change (%)0.00 (0.00%)
Volume0
Data as of 09/22/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.


Upcoming Events


La Jolla Pharmaceutical Company at the Cantor Fitzgerald Global Healthcare Conference
Monday, September 25, 2017 4:10 p.m. ET
Add to Calendar Add La Jolla Pharmaceutical Company at the Cantor Fitzgerald Global Healthcare Conference to Calendar  Help



Recent News


La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018

09/25/17

-- Decision follows successful Scientific Advice meeting with European Medicines Agency -- SAN DIEGO--(BUSINESS WIRE)--Sep. 25, 2017-- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) toda

Read More

Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State

09/20/17

Analysis to Be Presented in Oral Session at the 30th Annual Congress of The European Society of Intensive Care Medicine SAN DIEGO--(BUSINESS WIRE)--Sep. 20, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Co

Read More

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501

08/28/17

– Priority Review Granted – SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.S. Food and Drug Administration (FDA) h

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts